undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp revenue

Bionexus Gene Lab Corp's revenue was $7.4m in fiscal 2025, down 21.9% on the year before. Since fiscal 2018 ($212,328) it has grown at a compound 66.2% a year. Over the last twelve months it was $3.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00111311101073
Growth on the year before—−40.2%+>999%+17.3%−18.2%−10.6%−2.7%−21.9%—
Gross profit002211110

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
Malaysia $5.8M 78.5% ▼ 21.8%
MV $680,994 9.2% ▼ 10.6%
LK $452,639 6.1% ▼ 1.4%
Singapore $240,757 3.2% ▼ 57.9%
ID $114,867 1.5% ▼ 16.9%
BD $106,253 1.4% ▼ 13.8%

From Bionexus Gene Lab Corp's 10-K filed April 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bionexus Gene Lab Corp $3.1m -67.3% -32.9%
Quantum-si Inc $1.6m -53.0% 51.8%
Seer, Inc. $14.2m -12.7% -5.1%
YD Bio Ltd $596,817 16.9% —
Ispecimen Inc. $466,302 -92.1% -64.1%
Bionano Genomics, Inc. $30.2m 10.0% -1.4%

Compare with peers

Head to head: BGLC vs QSIBGLC vs SEERBGLC vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionexus Gene Lab Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionexus Gene Lab Corp.